Brain Distribution of Berzosertib: An Ataxia Telangiectasia and Rad3-Related Protein Inhibitor for the Treatment of Glioblastoma

Keyphrases

• Glioblastoma 100%
• Brain Distribution 100%
• Proteinase Inhibitor 100%
• Rad3 100%
• Ataxia Telangiectasia 100%
• Berzosertib 100%
• Blood-brain Barrier 41%
• Glioblastoma multiforme 33%
• Tumor 16%
• Radiotherapy 16%
• Chemotherapy 16%
• Temozolomide 16%
• Brain Tumor 16%
• Brain Tissue 16%
• Free Drug Concentration 16%
• In Cancer 8%
• Effective Treatment 8%
• Tumor Model 8%
• Tumor Cells 8%
• DNA Damage Response 8%
• Poor Prognosis 8%
• Protein Kinase 8%
• Response Network 8%
• Cell Toxicity 8%
• Drug Delivery 8%
• DNA Repair 8%
• Cancer Cells 8%
• In Vivo Efficacy 8%
• In Vitro Study 8%
• Synergistic Effect 8%
• Primary Brain Tumor 8%
• Clinical Utility 8%
• Normal Brain 8%
• Tissue Binding 8%
• Binding Affinity 8%
• Efflux 8%
• Invasive Tumors 8%
• Intracranial Tumor 8%
• Patient-derived Xenograft 8%
• DNA Damage Response Pathway 8%
• Brain Delivery 8%
• Tumor Core 8%
• Standard-of-care Therapy 8%
• Cancer Inhibition 8%

Pharmacology, Toxicology and Pharmaceutical Science

• Glioblastoma 100%
• Protein Inhibitor 100%
• ATR Protein 100%
• Berzosertib 100%
• Neoplasm 41%
• Blood-Brain Barrier 41%
• Intracranial Tumor 25%
• Chemotherapy 16%
• Drug Concentration 16%
• Temozolomide 16%
• Efficacy Study 8%
• Malignant Neoplasm 8%
• Tumor Model 8%
• Effusion 8%
• Protein Kinases 8%
• Cytotoxicity 8%